9 research outputs found

    Una estimación de los trabajadores desanimados en la provincia de Segovia

    Get PDF
    En este trabajo se estudia la variación de la oferta laboral y su relación con el ciclo económico. El objetivo principal es conocer la predominancia del efecto del trabajador “desanimado” o, por el contrario, el efecto del trabajador “añadido para España, Castilla y León y para las provincias de Castilla y León, en un periodo temporal que abarca desde 1977 hasta el año 2014. Además también se hace una estimación para conocer el volumen de trabajadores añadidos y desanimados para los territorios estudiados, en un periodo que va desde el año 2008 hasta el año 2014, periodo denominado como la “gran recesión”. Ambos efectos se suelen dar en épocas de recesión donde la hipótesis del trabajador “desanimado” implica una infraestimación del desempleo y la hipótesis del trabajador “añadido” conlleva una sobrestimación del desempleo. Como conclusión podemos decir que el efecto del trabajador “desanimado” predomina sobre el trabajador “añadido” para los territorios estudiados.Grado en Administración y Dirección de Empresa

    Desarrollo de una herramienta software para la cuantificación de secuencias de vídeo e imágenes de termografía infrarroja en el diagnóstico y seguimiento del Síndrome de Dolor Regional Complejo

    Full text link
    [ES] El Síndrome de Dolor Regional Complejo (SDRC) es una afección de dolor crónico que consiste en un dolor intenso que se concentra en las extremidades superiores e inferiores. Este síndrome se suele producir tras una lesión en un nervio o en el tejido del área afectada. No existe un tratamiento que permita curar el síndrome, todo lo que existe actualmente permite paliar los síntomas y disminuir el dolor. Uno de los tratamientos terapéuticos que se llevan a cabo para las extremidades inferiores son los Bloqueos Simpáticos Lumbares. Para colocación de la aguja, el guiado de la técnica se realiza mediante fluoroscopia. Previo a la administración de la medicación, se realiza un test de lidocaína para comprobar si la localización de la aguja es la adecuada. Para ello, se observa mediante las imágenes termográficas durante un intervalo de tiempo si aumenta la temperatura de la planta del pie. En caso afirmativo, se administra la medicación correspondiente y, por lo contrario, si no se observan cambios en la temperatura, se recoloca la aguja y se repite el procedimiento. Este trabajo propone una herramienta que permita detectar mínimas variaciones significativas de temperatura que permitan determinar la localización precisa de inyección del fármaco. La idea es realizar la detección en el menor tiempo posible y evitar realizar más de un intento para localizar el punto de inyección de la levobupivacaína, fármaco empleado en el tratamiento. La punción de esa zona varias veces puede suponer un riesgo para el paciente al ser una zona con vasos sanguíneos importantes que pueden ser perforados y producir una hemorragia. Las imágenes para analizar se adquirieron mediante termografía infrarroja, una técnica que permite obtener la temperatura superficial de los cuerpos, en este caso de los pies, a partir de la radiación emitida por éstos. Los resultados del trabajo han sido satisfactorios pues se ha conseguido desarrollar una herramienta de cuantificación de secuencias radiométricas que ha permitido introducir una serie de parámetros cuantitativos y objetivos. Esto supone un gran avance debido a la subjetividad a la que se someten este tipo de tratamientos que se basan principalmente en la percepción del paciente.[EN] Complex Regional Pain Syndrome (CRPS) is a chronic pain condition consisting of severe pain that is concentrated in the upper and lower limbs. This syndrome usually occurs after injury to a nerve or tissue in the affected area. There is no treatment that allows curing the syndrome, everything that is known is related to the palliation of symptoms and pain relief. One of the therapeutic treatments carried out for the lower limbs is the Lumbar Sympathetic Blocks. For needle placement, the technique is guided by fluoroscopy. Before administering the medication, a test of lidocaine is performed to verify if the location of the needle is adequate. For it, it is observed by means of thermographic images during a time interval if the temperature of the soleo of the foot increases. If so, the corresponding medication is administered and, on the contrary, if no changes in temperature are observed, the needle is repositioned and the procedure is repeated. This work proposes a tool that allows minimum specific temperature variations detection that will determine the precise location of drug injection. The idea is to carry out the detection in the shortest possible time and to avoid carrying out more than one attempt to locate the luvobupinacaine injection site. The repeated spinal tap of that area can entail a risk to the patient since there are an area with important blood vessels that can be perforated and cause a hemorrhage. The images to be analyzed will be acquired using infrared thermography, a technique that allows obtaining the surface temperature of the bodies, in this case the temperature of the feet, from the radiation emitted by them. The aim of this Master's Thesis is, therefore, to develop the tool described above. For this purpose, the creation, using MATLAB, of a software with a graphical interface that allows the user to analyze previously acquired thermographic images is proposed. Video sequences of infrared thermography of the soles of the feet of several patients will be available, in which the region of interest will be segmented and analyzed, in order to obtain characteristic parameters that vary over time and allow the diagnosis and characterization of CRPS. The results of the project have been satisfactory as it has been possible to develop a radiometric sequence quantification tool that has allowed the introduction of a series of quantitative and objective parameters. This implies a great advance due to the subjectivity to which these types of treatments are subjected, which are mainly based on the perception of the patient.Rubio Mayo, P. (2020). Desarrollo de una herramienta software para la cuantificación de secuencias de vídeo e imágenes de termografía infrarroja en el diagnóstico y seguimiento del Síndrome de Dolor Regional Complejo. Universitat Politècnica de València. http://hdl.handle.net/10251/163434TFG

    TransformEHRs: a flexible methodology for building transparent ETL processes for EHR reuse

    Get PDF
    Background: During the COVID-19 pandemic, several methodologies were designed for obtaining electronic health record (EHR)-derived datasets for research. These processes are often based on black boxes, on which clinical researchers are unaware of how the data were recorded, extracted, and transformed. In order to solve this, it is essential that extract, transform, and load (ETL) processes are based on transparent, homogeneous, and formal methodologies, making them understandable, reproducible, and auditable. Objectives: This study aims to design and implement a methodology, according with FAIR Principles, for building ETL processes (focused on data extraction, selection, and transformation) for EHR reuse in a transparent and flexible manner, applicable to any clinical condition and health care organization. Methods: The proposed methodology comprises four stages: (1) analysis of secondary use models and identification of data operations, based on internationally used clinical repositories, case report forms, and aggregated datasets; (2) modeling and formalization of data operations, through the paradigm of the Detailed Clinical Models; (3) agnostic development of data operations, selecting SQL and R as programming languages; and (4) automation of the ETL instantiation, building a formal configuration file with XML. Results: First, four international projects were analyzed to identify 17 operations, necessary to obtain datasets according to the specifications of these projects from the EHR. With this, each of the data operations was formalized, using the ISO 13606 reference model, specifying the valid data types as arguments, inputs and outputs, and their cardinality. Then, an agnostic catalog of data was developed through data-oriented programming languages previously selected. Finally, an automated ETL instantiation process was built from an ETL configuration file formally defined. Conclusions: This study has provided a transparent and flexible solution to the difficulty of making the processes for obtaining EHR-derived data for secondary use understandable, auditable, and reproducible. Moreover, the abstraction carried out in this study means that any previous EHR reuse methodology can incorporate these results into them.Ministerio de Economía y Competitividad Instituto de Salud Carlos III PI18/00981, PI18/01047, PI18CIII/00019.S

    Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Get PDF
    Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

    Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice : A multicentre cohort study

    Get PDF
    Background: The aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS). Methods: Treatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014-2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL) < 50 copies/ml and < 200 copies/ml at 24 and 48 weeks after starting this regimen, stratified by baseline VL (< 50 or ≥ 50 copies/ml at the start of the regimen). Results: We included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL < 50 copies/ml and 29 (74.4%) had ≥ 50 copies/ml. Among patients with baseline VL < 50 copies/ml, 85.7% and 80.0% had VL < 50 copies/ml at 24 and 48 weeks, respectively, and 100% had VL < 200 copies/ml at 24 and 48 weeks. Among patients with baseline VL ≥ 50 copies/ml, 42.3% and 40.9% had VL < 50 copies/ml and 69.2% and 68.2% had VL < 200 copies/ml at 24 and 48 weeks. During the first 48 weeks, no patients changed their treatment due to toxicity, and 4 patients (all with baseline VL ≥ 50 copies/ml) changed due to virological failure. Conclusions: EVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads

    How do women living with HIV experience menopause? Menopausal symptoms, anxiety and depression according to reproductive age in a multicenter cohort

    Get PDF
    CatedresBackground: To estimate the prevalence and severity of menopausal symptoms and anxiety/depression and to assess the differences according to menopausal status among women living with HIV aged 45-60 years from the cohort of Spanish HIV/AIDS Research Network (CoRIS). Methods: Women were interviewed by phone between September 2017 and December 2018 to determine whether they had experienced menopausal symptoms and anxiety/depression. The Menopause Rating Scale was used to evaluate the prevalence and severity of symptoms related to menopause in three subscales: somatic, psychologic and urogenital; and the 4-item Patient Health Questionnaire was used for anxiety/depression. Logistic regression models were used to estimate odds ratios (ORs) of association between menopausal status, and other potential risk factors, the presence and severity of somatic, psychological and urogenital symptoms and of anxiety/depression. Results: Of 251 women included, 137 (54.6%) were post-, 70 (27.9%) peri- and 44 (17.5%) pre-menopausal, respectively. Median age of onset menopause was 48 years (IQR 45-50). The proportions of pre-, peri- and post-menopausal women who had experienced any menopausal symptoms were 45.5%, 60.0% and 66.4%, respectively. Both peri- and post-menopause were associated with a higher likelihood of having somatic symptoms (aOR 3.01; 95% CI 1.38-6.55 and 2.63; 1.44-4.81, respectively), while post-menopause increased the likelihood of having psychological (2.16; 1.13-4.14) and urogenital symptoms (2.54; 1.42-4.85). By other hand, post-menopausal women had a statistically significant five-fold increase in the likelihood of presenting severe urogenital symptoms than pre-menopausal women (4.90; 1.74-13.84). No significant differences by menopausal status were found for anxiety/depression. Joint/muscle problems, exhaustion and sleeping disorders were the most commonly reported symptoms among all women. Differences in the prevalences of vaginal dryness (p = 0.002), joint/muscle complaints (p = 0.032), and sweating/flush (p = 0.032) were found among the three groups. Conclusions: Women living with HIV experienced a wide variety of menopausal symptoms, some of them initiated before women had any menstrual irregularity. We found a higher likelihood of somatic symptoms in peri- and post-menopausal women, while a higher likelihood of psychological and urogenital symptoms was found in post-menopausal women. Most somatic symptoms were of low or moderate severity, probably due to the good clinical and immunological situation of these women

    International comparisons of laboratory values from the 4CE collaborative to predict COVID-19 mortality

    No full text
    International audienceAbstract Given the growing number of prediction algorithms developed to predict COVID-19 mortality, we evaluated the transportability of a mortality prediction algorithm using a multi-national network of healthcare systems. We predicted COVID-19 mortality using baseline commonly measured laboratory values and standard demographic and clinical covariates across healthcare systems, countries, and continents. Specifically, we trained a Cox regression model with nine measured laboratory test values, standard demographics at admission, and comorbidity burden pre-admission. These models were compared at site, country, and continent level. Of the 39,969 hospitalized patients with COVID-19 (68.6% male), 5717 (14.3%) died. In the Cox model, age, albumin, AST, creatine, CRP, and white blood cell count are most predictive of mortality. The baseline covariates are more predictive of mortality during the early days of COVID-19 hospitalization. Models trained at healthcare systems with larger cohort size largely retain good transportability performance when porting to different sites. The combination of routine laboratory test values at admission along with basic demographic features can predict mortality in patients hospitalized with COVID-19. Importantly, this potentially deployable model differs from prior work by demonstrating not only consistent performance but also reliable transportability across healthcare systems in the US and Europe, highlighting the generalizability of this model and the overall approach

    Characterization of long COVID temporal sub-phenotypes by distributed representation learning from electronic health record data: a cohort studyResearch in Context

    No full text
    Summary: Background: Characterizing Post-Acute Sequelae of COVID (SARS-CoV-2 Infection), or PASC has been challenging due to the multitude of sub-phenotypes, temporal attributes, and definitions. Scalable characterization of PASC sub-phenotypes can enhance screening capacities, disease management, and treatment planning. Methods: We conducted a retrospective multi-centre observational cohort study, leveraging longitudinal electronic health record (EHR) data of 30,422 patients from three healthcare systems in the Consortium for the Clinical Characterization of COVID-19 by EHR (4CE). From the total cohort, we applied a deductive approach on 12,424 individuals with follow-up data and developed a distributed representation learning process for providing augmented definitions for PASC sub-phenotypes. Findings: Our framework characterized seven PASC sub-phenotypes. We estimated that on average 15.7% of the hospitalized COVID-19 patients were likely to suffer from at least one PASC symptom and almost 5.98%, on average, had multiple symptoms. Joint pain and dyspnea had the highest prevalence, with an average prevalence of 5.45% and 4.53%, respectively. Interpretation: We provided a scalable framework to every participating healthcare system for estimating PASC sub-phenotypes prevalence and temporal attributes, thus developing a unified model that characterizes augmented sub-phenotypes across the different systems. Funding: Authors are supported by National Institute of Allergy and Infectious Diseases, National Institute on Aging, National Center for Advancing Translational Sciences, National Medical Research Council, National Institute of Neurological Disorders and Stroke, European Union, National Institutes of Health, National Center for Advancing Translational Sciences

    Clinical phenotypes and outcomes in children with multisystem inflammatory syndrome across SARS-CoV-2 variant eras: a multinational study from the 4CE consortiumResearch in context

    No full text
    Summary: Background: Multisystem inflammatory syndrome in children (MIS-C) is a severe complication of SARS-CoV-2 infection. It remains unclear how MIS-C phenotypes vary across SARS-CoV-2 variants. We aimed to investigate clinical characteristics and outcomes of MIS-C across SARS-CoV-2 eras. Methods: We performed a multicentre observational retrospective study including seven paediatric hospitals in four countries (France, Spain, U.K., and U.S.). All consecutive confirmed patients with MIS-C hospitalised between February 1st, 2020, and May 31st, 2022, were included. Electronic Health Records (EHR) data were used to calculate pooled risk differences (RD) and effect sizes (ES) at site level, using Alpha as reference. Meta-analysis was used to pool data across sites. Findings: Of 598 patients with MIS-C (61% male, 39% female; mean age 9.7 years [SD 4.5]), 383 (64%) were admitted in the Alpha era, 111 (19%) in the Delta era, and 104 (17%) in the Omicron era. Compared with patients admitted in the Alpha era, those admitted in the Delta era were younger (ES −1.18 years [95% CI −2.05, −0.32]), had fewer respiratory symptoms (RD −0.15 [95% CI −0.33, −0.04]), less frequent non-cardiogenic shock or systemic inflammatory response syndrome (SIRS) (RD −0.35 [95% CI −0.64, −0.07]), lower lymphocyte count (ES −0.16 × 109/uL [95% CI −0.30, −0.01]), lower C-reactive protein (ES −28.5 mg/L [95% CI −46.3, −10.7]), and lower troponin (ES −0.14 ng/mL [95% CI −0.26, −0.03]). Patients admitted in the Omicron versus Alpha eras were younger (ES −1.6 years [95% CI −2.5, −0.8]), had less frequent SIRS (RD −0.18 [95% CI −0.30, −0.05]), lower lymphocyte count (ES −0.39 × 109/uL [95% CI −0.52, −0.25]), lower troponin (ES −0.16 ng/mL [95% CI −0.30, −0.01]) and less frequently received anticoagulation therapy (RD −0.19 [95% CI −0.37, −0.04]). Length of hospitalization was shorter in the Delta versus Alpha eras (−1.3 days [95% CI −2.3, −0.4]). Interpretation: Our study suggested that MIS-C clinical phenotypes varied across SARS-CoV-2 eras, with patients in Delta and Omicron eras being younger and less sick. EHR data can be effectively leveraged to identify rare complications of pandemic diseases and their variation over time. Funding: None
    corecore